Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) EBT Margin (2016 - 2025)

KalVista Pharmaceuticals' EBT Margin history spans 7 years, with the latest figure at 224.74% for Q2 2020.

  • On a quarterly basis, EBT Margin rose 14707.0% to 224.74% in Q2 2020 year-over-year; TTM through Jul 2024 was 741.41%, a N/A change, with the full-year FY2025 number at 803.71%, down 69839.0% from a year prior.
  • EBT Margin hit 224.74% in Q2 2020 for KalVista Pharmaceuticals, up from 783.26% in the prior quarter.
  • Over the last five years, EBT Margin for KALV hit a ceiling of 60.0% in Q2 2018 and a floor of 94342.86% in Q1 2016.
  • Historically, EBT Margin has averaged 6669.14% across 5 years, with a median of 371.8% in 2019.
  • Biggest five-year swings in EBT Margin: crashed -2028571bps in 2016 and later skyrocketed 549200bps in 2018.
  • Tracing KALV's EBT Margin over 5 years: stood at 2038.07% in 2016, then skyrocketed by 74bps to 526.71% in 2017, then surged by 84bps to 83.85% in 2018, then plummeted by -167bps to 224.08% in 2019, then fell by 0bps to 224.74% in 2020.
  • Business Quant data shows EBT Margin for KALV at 224.74% in Q2 2020, 783.26% in Q1 2020, and 224.08% in Q4 2019.